Որոնման արդյունքները - Anouk C. Vedder
- Ցուցադրվում են 1 - 3 արդյունքները 3
-
1
Sustained, Long-Term Renal Stabilization After 54 Months of Agalsidase β Therapy in Patients with Fabry Disease Dominique P. Germain, Stephen Waldek, Maryam Banikazemi, David A. Bushinsky, Joel Charrow, Robert J. Desnick, Philip Lee, Thomas Loew, Anouk C. Vedder, Rekha Abichandani, William R. Wilcox, Nathalie Guffon
Հրապարակվել է 2007Artigo -
2
Treatment of Fabry Disease: Outcome of a Comparative Trial with Agalsidase Alfa or Beta at a Dose of 0.2 mg/kg Anouk C. Vedder, Gabor E. Linthorst, Gunnar Houge, Johannna E.M. Groener, Els E. Ormel, Berto J. Bouma, Johannes M. F. G. Aerts, Asle Hirth, Carla E. M. Hollak
Հրապարակվել է 2007Artigo -
3
Elevated globotriaosylsphingosine is a hallmark of Fabry disease Johannes M. F. G. Aerts, J.E.M. Groener, Sijmen Kuiper, Wilma E. Donker‐Koopman, Anneke Strijland, Roelof Ottenhoff, Cindy van Roomen, Mina Mirzaian, Frits A. Wijburg, Gabor E. Linthorst, Anouk C. Vedder, Saskia M. Rombach, Josanne Cox‐Brinkman, Pentti Somerharju, Rolf G. Boot, Carla E. M. Hollak, Roscoe O. Brady, Ben J. H. M. Poorthuis
Հրապարակվել է 2008Artigo
Որոնման գործիքներ:
Առնչվող խորագիր
Disease
Enzyme replacement therapy
Fabry disease
Globotriaosylceramide
Internal medicine
Medicine
Adverse effect
Creatinine
Endocrinology
Pathology
Renal function
Surgery
Urology
Alpha-galactosidase
Alternative medicine
Biochemistry
Biology
Dose
Fabry's disease
Gastroenterology
Kidney
Kidney disease
Metabolite
Pathogenesis
Placebo
Proteinuria
Randomized controlled trial
Sphingolipid
Tolerability